News | December 21, 2023
AGC invests US$ 348 million to expand its biopharmaceutical CDMO capability
Development services for gene and cell therapies is planned to begin first in 2025
Development services for gene and cell therapies is planned to begin first in 2025
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Weinand is the former CEO and Chairman of the Board at Bayer Pharma AG, leading Bayer’s fully integrated $20 billion healthcare business
Good momentum in commercial CDMO business
Under the terms of the collaboration, Vertex and Lonza will partner in the process development and scale-up for the manufacturing of the product portfolio and co-invest to build a dedicated new facility in Portsmouth, New Hampshire (US)
One thousand times more soluble than L-cystine at neutral pH
The San Francisco facility is part of Thermo Fisher’s global pharma services network of more than 15 locations supporting cell and gene therapies.
GlobalData’s ‘Pharmaceutical Intelligence Center’ observes that India is still in the nascent stage of developing these potential therapies as currently only four cell/gene therapy molecules are being developed in the country.
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
Subscribe To Our Newsletter & Stay Updated
